{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:07:55Z","timestamp":1791122875065,"version":"4.1.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40265-025-02260-3","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T08:33:19Z","timestamp":1764145999000},"page":"259-263","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Paltusotine: First Approval"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-7831","authenticated-orcid":false,"given":"Arnold","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"issue":"11","key":"2260_CR1","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","volume":"10","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Langlois F, Lim DST, et al. Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2022;10(11):804\u201326.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2260_CR2","first-page":"32","volume":"20","author":"DS McLaren","year":"2024","unstructured":"McLaren DS, Seejore K, Lynch J, et al. Oral octreotide capsules and paltusotine in management of acromegaly. touchREV Endocrinol. 2024;20(1):32\u20136.","journal-title":"touchREV Endocrinol."},{"key":"2260_CR3","unstructured":"Crinetics Pharmaceuticals, Inc,. Crinetics announces FDA approval of PALSONIFY\u2122 (paltusotine) for the treatment of acromegaly in adults [media release]. 25 Sep 2025. https:\/\/crinetics.com\/."},{"key":"2260_CR4","unstructured":"Crinetics Pharmaceuticals, Inc. PALSONIFY (paltusotine) tablets: US prescribing information. 2025. https:\/\/crinetics.com\/PALSONIFY_PI\/. Accessed 2 Oct 2025."},{"key":"2260_CR5","unstructured":"Crinetics P. Crinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho enter into exclusive licensing agreement for the development and commercialization of paltusotine in Japan [media release]. 28 Feb 2022. http:\/\/www.crinetics.com."},{"issue":"2","key":"2260_CR6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s11102-021-01201-z","volume":"25","author":"A Madan","year":"2022","unstructured":"Madan A, Markison S, Betz SF, et al. Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers. Pituitary. 2022;25(2):328\u201339.","journal-title":"Pituitary"},{"issue":"1","key":"2260_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1210\/clinem\/dgae385","volume":"110","author":"MR Gadelha","year":"2024","unstructured":"Gadelha MR, Casagrande A, Strasburger CJ, et al. Acromegaly disease control maintained after switching from injected somatostatin receptor ligands to oral paltusotine. J Clin Endocrinol Metab. 2024;110(1):228\u201337.","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl. 1","key":"2260_CR8","first-page":"A625","volume":"8","author":"BM Biller","year":"2024","unstructured":"Biller BM, Casagrande A, Elenkova A, et al. Efficacy and safety of once-daily oral paltusotine In medically untreated patients with acromegaly: results from the phase 3, randomized, placebo-controlled PATHFNDR-2 study [abstract no. 12535 plus Poster]. J Endocr Soc. 2024;8(Suppl. 1):A625\u20136.","journal-title":"J Endocr. Soc."},{"key":"2260_CR9","doi-asserted-by":"crossref","unstructured":"Rizio AA, Carty MK, Krasner A, et al. Effects of paltusotine treatment on patient-reported symptoms of acromegaly in phase 3 randomized placebo-controlled studies (PATHFNDR-1 and PATHFNDR-2) [abstract no. SUN-052]. In: Endocrine Society Annual Meeting (ENDO). 2025.","DOI":"10.1210\/jendso\/bvaf149.1637"},{"key":"2260_CR10","doi-asserted-by":"crossref","unstructured":"Gadelha MR, Casagrande A, Elenkova A, et al. Once-daily oral paltusotine in the treatment of patients with biochemically uncontrolled acromegaly: interim results of the PATHFNDR-2 open-label extension [abstract no. MON-069]. In: Endocrine Society Annual Meeting (ENDO). 2025.","DOI":"10.1210\/jendso\/bvaf149.1400"},{"key":"2260_CR11","doi-asserted-by":"crossref","unstructured":"Biller BMK, Casagrande A, Strasburger CJ, et al. Disease control in patients with acromegaly switching from injected somatostatin receptor ligands to once-daily oral paltusotine: interim results of the PATHFNDR-1 open-label extension [abstract plus Presentation]. In: Endocrine Society Annual Meeting (ENDO). 2025.","DOI":"10.1210\/jendso\/bvaf149.1474"},{"issue":"5","key":"2260_CR12","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1210\/clinem\/dgac643","volume":"108","author":"MR Gadelha","year":"2023","unstructured":"Gadelha MR, Gordon MB, Doknic M, et al. Acrobat edge: safety and efficacy of switching injected SRLs to oral paltusotine in patients with acromegaly. J Clin Endocrinol Metab. 2023;108(5):e148\u201359.","journal-title":"J Clin Endocrinol Metab"},{"key":"2260_CR13","doi-asserted-by":"crossref","unstructured":"Gadelha MR, Randeva HS, Gordon MB, et al. Long-term safety and efficacy of once-daily oral paltusotine in the treatment of patients with acromegaly: ACROBAT advance year 4 analysis [abstract no. P973]. In: Endocrine Abstracts. 2025.","DOI":"10.1210\/jendso\/bvae163.1269"},{"key":"2260_CR14","doi-asserted-by":"crossref","unstructured":"Chauhan A, Mohamed A, Usiskin K, et al. Once-daily oral paltusotine in the treatment of patients with carcinoid syndrome: results from a phase 2, randomized, parallel-group study [abstract no. ID28555]. In: Endocrine Abstracts. 2024.","DOI":"10.1530\/endoabs.99.P498"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02260-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02260-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02260-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:58:01Z","timestamp":1769849881000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02260-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2260"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02260-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Arnold Lee is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}